Thousands of individuals were ready to get vaccinated this Friday in Seattle within the middle of the night, within the state of Washington, thanks to the failure of a freezer that stored 1,650 doses of Moderna’s coronavirus vaccine. The doses of Moderna are administered in various health centers within the city to thousands of individuals who learned the news through social networks and approached medical centers. At the instant, it’s unknown what caused the failure within the freezer that stored the vaccines.
Through a tweet on the official account of the health organization ‘Swedish’ that operates in Seattle, the supply of 588 doses of Moderna’s vaccine was announced, which might be administered during 4 hours at the University clinics from Seattle and therefore the University of Washington. Within two hours, all appointments were sold out, which might be requested on the web site of this organization.
The director of operations of ‘Swedish’, Kevin Brooks, has assured that “no dose has been wasted because they need been delivered to a different health organization”, as he has declared to the tv network NBC.Several people have also queued at the door of the clinic and therefore the parking zone of the UW Medical Center-Northwest of the town, although many of these who have crowded within the center were too young and didn’t meet the wants of the state of Washington to urge vaccinated during this first phase.
The Washington State Hospital Association has also confirmed that no dose has been wasted which it’s communicated with the Washington State Department of Health so that all people vaccinated this Friday receive the second dose, consistent with the DPA agency. .On the opposite hand, the CEO of Pfizer, Albert Bourla, participated this Friday during a teleconference on the fight against COVID-19 during the Judgment Day of the Davos Forum and warned that given the mutations of the coronavirus, it’s highly probable that it’ll arise some variant against which the (current) vaccines aren’t effective. However, he stressed that “this isn’t yet the case” which his company is functioning to adapt its products to those future possible new strains.
I think there’s a high possibility that at some point a replacement variant will appear which the vaccines won’t be as effective. this is often not the case yet, but I feel it’s very likely that at some point it’ll happen, said Bourla. And, about this eventual scenario, he affirmed that the corporate is functioning to adapt its inoculant so that within 100 days or less after it happens we have a replacement version of the vaccine and that we can maintain the high level of efficacy when administering it.
On the opposite hand, Bourla mentioned the very fact that now that vaccines became available everyone wants to possess them, and there are political tensions that affect governments.”In the case of Pfizer, he recalled, these tensions occurred recently thanks to problems within the shipment of doses to Europe, We had a little downturn that affected the availability line, but we are making an attempt to dramatically improve our production capacity, he said.
As a result of this effort, Pfizer estimates that this year it’ll be ready to produce quite 2 billion doses (equivalent to immunize quite one-eighth of the world’s population), once they had initially projected 1.3 billion. In Europe, the quantities promised in December will already be available in March, and that we will deliver more within the second quarter, he said.